Lafaval

Tadalafil, the active ingredient in Lafaval, is a phosphodiesterase type 5 (PDE5) inhibitor presented as a tablet for oral use. It is prescribed for erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension in adult males.

GNH USA supplies Lafaval as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lafaval (tadalafil) acts on the phosphodiesterase type 5 pathway and is indicated for several vascular‑related conditions. - Erectile dysfunction: improves ability to achieve and maintain an erection when sexual stimulation occurs. - Benign prostatic hyperplasia: relieves urinary symptoms such as reduced flow and urgency. - Pulmonary arterial hypertension: enhances exercise capacity by lowering pulmonary vascular resistance.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain in the head. - Dyspepsia: upset stomach or indigestion. - Back pain: muscular discomfort, often transient. - Nasal congestion: blocked or runny nose. - Flushing: warmth and redness of the face. - Vision changes: blurred or altered color perception.

Serious or Rare Side Effects: - Sudden vision loss: may indicate non‑arteritic anterior ischemic optic neuropathy. - Sudden hearing loss: unexplained decrease in hearing ability. - Priapism: prolonged erection lasting more than 4 hours. - Cardiovascular events: chest pain, arrhythmia, or stroke in susceptible individuals. - Severe hypotension: marked drop in blood pressure, especially with nitrates. - Allergic reactions: rash, itching, or swelling of the face and throat.

Before prescribing Lafaval, clinicians should assess patient history and comorbidities. - Cardiovascular disease: evaluate risk of myocardial infarction or stroke. - Nitrate therapy: avoid concurrent use due to risk of severe hypotension. - Renal or hepatic impairment: consider dose adjustment or monitoring. - Concomitant alpha‑blockers: monitor blood pressure for additive effects. - Visual disorders: caution in patients with retinal disease. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Tadalafil may interact with several medication classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): can cause profound hypotension. - Guanylate cyclase stimulators (e.g., riociguat): risk of excessive blood pressure lowering. - Other PDE5 inhibitors: may lead to additive vasodilatory effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase tadalafil plasma levels. - Antihypertensives (e.g., alpha‑blockers): may enhance blood pressure reduction. - Alpha‑adrenergic antagonists (e.g., doxazosin): monitor for dizziness or fainting.